Avacta Group plc (RTQ1) AI Stock Analysis

3 Followers

Avacta Group plc

(Frankfurt:RTQ1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Proprietary oncology platformsProprietary Affimer and pre|CISION platforms give Avacta a differentiated technology base in targeted oncology. If development progresses, these platforms can support multiple drug candidates and create longer-term partnering, licensing, milestone, or royalty opportunities.

Negative Factors

Persistent unprofitabilityPersistent operating and net losses show that current activities are not yet converting into sustainable earnings. The negative gross profit in 2025 further indicates an unstable cost structure, making profitability dependent on substantial operational improvement or future product commercialization.

Avacta Group plc (RTQ1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 290.61M
Dividend Yield: ―
Average Volume (3M): 4,854
Price to Earnings (P/E): -6.5
Beta (1Y): -0.60
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 81
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Avacta Group plc Business Overview & Revenue Model

Company Description

Avacta Group Plc operates as a clinical-stage biopharmaceutical company, specializing in the development of cancer therapies and diagnostic solutions. These advancements are driven by its proprietary Affimer and pre|CISION technology platforms, with...

Avacta Group plc Earnings Call Summary

Earnings Call Date:May 19, 2026(Q4-2025)|% Change Since:-36.92%|Next Earnings Date:Oct 18, 2019

Earnings Call SentimentPositive

The call presented multiple important positive developments: on-time clinical execution (first-in-human dosing for AVA6103), promising preclinical metrics (up to ~40x tumor Cmax and ~3x tumor selectivity), strengthened IP, focused R&D investment (+31.5% YoY), cost reductions and a successful recent fundraising that extends runway into early Q1 2027. Offsetting these positives are meaningful near-term financing and timeline risks — limited cash runway without partner income, dependence on partnership to launch pivotal studies, tolerability/dose-selection questions at higher AVA6000 doses, and delays/hold status for the Affimer program. On balance the call emphasized substantive scientific and clinical progress alongside manageable but material financing and timing risks.

Positive Updates

Clinical Milestone — AVA6103 First Patient Dosed

First patient dosed in FOCUS-01 Phase I (AVA6103) on time in March 2026; multicenter US-focused trial enrolling 6 advanced cancers with initial clinical data committed by end of 2026 (late Q4).

Negative Updates

Limited Near-Term Cash Runway and Financing Dependency

Cash balance of GBP 16.4m provides runway only into early Q1 2027 assuming no partnering income; company did not disclose monthly burn and remains dependent on further financing or partnerships to fund clinical development beyond that point.

Company Guidance

The call guided a busy 2026 timetable and detailed financial and clinical metrics: R&D spend was GBP 18.8m in FY2025 (up from GBP 14.3m), administrative costs ~GBP 10m (down from GBP 12m), net operating cash outflow GBP 22.64m (vs GBP 24.94m in 2024), and the company has raised GBP 32.5m over the last 18 months (including an oversubscribed GBP 10m placing), leaving cash of GBP 16.4m at end-April 2026 and a runway into early Q1 2027 (assumes no partnering income). Clinically, AVA6103 (FOCUS‑01) dosed its first patient on time in March 2026, is enrolling across ~7–9 U.S. Phase Ia sites for six advanced tumor types (no UK centers), and initial Phase I data are expected by end‑2026 (late Q4); AVA6000 continues in Phase Ia/Ib with a recommended dose for expansion of 310 mg/m2 (other cohorts: 385, 385/200, 250) and Phase Ib/efficacy and cardiac‑safety data to be presented H1 2026 (ASCO/BIO). Pipeline timing also includes AVA6207 payload disclosures targeted in Q3 2026 and candidate selection in H2 2026; preclinical metrics cited include up to 40x higher tumor Cmax for released exatecan versus daruxtecan and ~3x higher tumor selectivity index versus ADCs, and the platform targets FAP expressed in ~90% of solid tumors.

Avacta Group plc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:RTQ1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:4BB	52Neutral	GBP 100.70M	-4.53	-316.73%	―	-56.10%	-16.77%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:PRTC	50Neutral	GBP 300.10M	167.28	0.14%	―	-4.11%	-96.92%
GB:SCLP	44Neutral	GBP 96.98M	-4.57	128.87%	―	-100.00%	-30.39%
GB:NFX	39Underperform	GBP 2.74M	-2.02	-83.53%	―	―	93.02%
GB:AREC	33Underperform	GBP 35.11M	155.00	3.75%	―	―	―

* Healthcare Sector Average

Performance Comparison

DE:RTQ1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:RTQ1	Avacta Group plc	0.61	-0.24	-28.07%
GB:NFX	Nuformix Plc	0.10	-0.19	-67.24%
GB:PRTC	PureTech Health	126.00	0.80	0.64%
GB:SCLP	Scancell Holdings	80.00	-20.00	-20.00%
GB:4BB	4basebio UK Societas	525.00	-187.50	-26.32%
GB:AREC	Arecor Therapeutics PLC	77.50	3.50	4.73%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Avacta Group plc AI Stock Analysis